India news from FierceBiotech
News
Merck turns to Ranbaxy for $100M R&D effort
India's Ranbaxy has flexed its research muscles once again, this time signing a five-year pact with Merck to develop new anti-infectives. Ranbaxy, which received an undisclosed upfront payment, says Read more...
Traditional remedies offer opportunities, challenges
The Financial Times delves into the push to develop new therapeutics from traditional Chinese and Indian remedies. There have been successes, including the anti-malarial artemether, which was Read more...
SPOTLIGHT: Biocon establishing R&D sub
India's Biocon says it will transfer four molecules to a new R&D subsidiary, resisting a trend in the subcontinent of spinning off R&D into a new company. Its researchers are working on new Read more...
India eyes R&D opportunities
India-based drugs have made a name for themselves as makers of copycat drugs. When a developer's lucrative drug goes off-patent, Indian companies are guaranteed to swoop in and make a less-expensive Read more...
SPOTLIGHT: Biocon denies buyout report
Biocon caused a stir this morning after an Indian financial newspaper claimed the country's Read more...
Affymetrix tech to be used in new gene study
India's Avesthagen has inked a deal to use Affymetrix's microarray technology in a genetic study involving 60,000 Parsi. The Avestagenome Project is studying the genetic foundation behind longevity. Read more...
Dr. Reddy's joins with 7TM on research pact
India's Dr. Reddy's Laboratories is teaming up with 7TM on a drug discovery deal for metabolic disorders. Both companies agreed to collaborate on selecting new drug candidates, jointly advancing them Read more...
BioCon buys stake in German pharma company
Fulfilling an earlier promise to acquire a company, Bangalor-based BioCon has spent €30 million to Read more...
Biocon CEO plans acquisition, spin-off
Biocon chief Kiran Mazumdar-Shaw says the Indian drug developer is close to completing a multimillion-dollar acquisition to push its products in North American and Europe and plans to spin off its Read more...
Forecast: BioPharma outsourcing will grow '08
Biotech and Big Pharma alike are taking outsourcing to new heights in 2008, according to IDC's Health Industry Insights report. This year everything from R&D to clinical trials and manufacturing Read more...
Get more India coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight